Search research articles
Contact Us
Filters
Showing results (81-90 of 157) with videos related to
Page
of 16
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 5, 2016
Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer
Sai-Hong Ignatius Ou, Ramaswamy Govindan, Keith D Eaton, et al.
Cancer Immunology, Immunotherapy : CII
|
February 24, 2021
Comparative assessment of manual chart review and ICD claims data in evaluating immunotherapy-related adverse events
Andrew Nashed, Shijun Zhang, Chien-Wei Chiang, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
July 10, 2012
First-line systemic therapy practice patterns and concordance with NCCN guidelines for patients diagnosed with metastatic NSCLC treated at NCCN institutions
Carrie Zornosa, Jonathan L Vandergrift, Gregory P Kalemkerian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 4, 2015
Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance)
Neal E Ready, Herbert H Pang, Lin Gu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 10, 2003
Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer
Miguel A Villalona-Calero, M Guillaume Wientjes, Gregory A Otterson, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine
|
October 16, 2012
Assessment of FANCD2 nuclear foci formation in paraffin-embedded tumors: a potential patient-enrichment strategy for treatment with DNA interstrand crosslinking agents
Wenrui Duan, Li Gao, Weiqiang Zhao, et al.
The Oncologist
|
October 4, 2016
A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer
Alberto A Chiappori, Gregory A Otterson, Afshin Dowlati, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 24, 2007
Phase I study of inhaled Doxorubicin for patients with metastatic tumors to the lungs
Gregory A Otterson, Miguel A Villalona-Calero, Sunil Sharma, et al.
Journal of Cancer Research and Clinical Oncology
|
August 2, 2019
Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers
Mingjia Li, Daniel Spakowicz, Jarred Burkart, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
March 4, 2014
NRAS isoforms differentially affect downstream pathways, cell growth, and cell transformation
Ann-Kathrin Eisfeld, Sebastian Schwind, Kevin W Hoag, et al.
Page
of 16
Search research articles
Search
Showing results (81-90 of 157) with videos related to
Sort By:
Page
of 16
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 5, 2016
Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer
Sai-Hong Ignatius Ou, Ramaswamy Govindan, Keith D Eaton, et al.
Cancer Immunology, Immunotherapy : CII
|
February 24, 2021
Comparative assessment of manual chart review and ICD claims data in evaluating immunotherapy-related adverse events
Andrew Nashed, Shijun Zhang, Chien-Wei Chiang, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
July 10, 2012
First-line systemic therapy practice patterns and concordance with NCCN guidelines for patients diagnosed with metastatic NSCLC treated at NCCN institutions
Carrie Zornosa, Jonathan L Vandergrift, Gregory P Kalemkerian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 4, 2015
Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance)
Neal E Ready, Herbert H Pang, Lin Gu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 10, 2003
Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer
Miguel A Villalona-Calero, M Guillaume Wientjes, Gregory A Otterson, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine
|
October 16, 2012
Assessment of FANCD2 nuclear foci formation in paraffin-embedded tumors: a potential patient-enrichment strategy for treatment with DNA interstrand crosslinking agents
Wenrui Duan, Li Gao, Weiqiang Zhao, et al.
The Oncologist
|
October 4, 2016
A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer
Alberto A Chiappori, Gregory A Otterson, Afshin Dowlati, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 24, 2007
Phase I study of inhaled Doxorubicin for patients with metastatic tumors to the lungs
Gregory A Otterson, Miguel A Villalona-Calero, Sunil Sharma, et al.
Journal of Cancer Research and Clinical Oncology
|
August 2, 2019
Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers
Mingjia Li, Daniel Spakowicz, Jarred Burkart, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
March 4, 2014
NRAS isoforms differentially affect downstream pathways, cell growth, and cell transformation
Ann-Kathrin Eisfeld, Sebastian Schwind, Kevin W Hoag, et al.
Page
of 16